Membership Directory - Corporate
CytoDel Inc
About
The Company’s patented technology enables recombinant derivatives of botulinum neurotoxin (BoT) to be engineered to create high value products with customized properties, including the ability to deliver therapeutic antibodies to targets inside neurons that are not accessible by conventional monoclonal antibodies.
Intraneuronal antibody delivery is achieved by creating a new class of BoT-based Antibody Fusion Proteins (AFPs), using atoxic derivatives of BoT as a molecular vehicle. The safety and efficacy of the AFP platform has been demonstrated in three species, including nonhuman primates. The lead AFP product, Cyto-111, is indicated for biodefense and two orphan indications. Cyto-111 is eligible for FDA approval via the Animal Rule. Cyto-111 fills an important gap in countermeasures to weaponized BoT, a Tier 1 Biodefense threat. Cyto-111 is also being developed for Orphan indications.
Recombinant BoT derivatives can undergo retrograde transport to the CNS , providing a mechanism for delivery to specific CNS regions along neuronal circuitry. This provides a privileged route for CNS delivery that circumvents the blood-brain barrier. Products to treat chronic pain syndromes and neurodegenerative diseases are in development.
CytoDel® Inc. was founded in 2012 to commercialize technology developed and patented by its founders at New York University School of Medicine (NYU). Discovery was supported by ~$15M in NIH funding. Development is currently funded by ~ $4M in Seed and Series A financing rounds, and ~$2.5M in DoD and SBIR funding. Series B financing is planned for the second half of 2023.
Intraneuronal antibody delivery is achieved by creating a new class of BoT-based Antibody Fusion Proteins (AFPs), using atoxic derivatives of BoT as a molecular vehicle. The safety and efficacy of the AFP platform has been demonstrated in three species, including nonhuman primates. The lead AFP product, Cyto-111, is indicated for biodefense and two orphan indications. Cyto-111 is eligible for FDA approval via the Animal Rule. Cyto-111 fills an important gap in countermeasures to weaponized BoT, a Tier 1 Biodefense threat. Cyto-111 is also being developed for Orphan indications.
Recombinant BoT derivatives can undergo retrograde transport to the CNS , providing a mechanism for delivery to specific CNS regions along neuronal circuitry. This provides a privileged route for CNS delivery that circumvents the blood-brain barrier. Products to treat chronic pain syndromes and neurodegenerative diseases are in development.
CytoDel® Inc. was founded in 2012 to commercialize technology developed and patented by its founders at New York University School of Medicine (NYU). Discovery was supported by ~$15M in NIH funding. Development is currently funded by ~ $4M in Seed and Series A financing rounds, and ~$2.5M in DoD and SBIR funding. Series B financing is planned for the second half of 2023.
